메뉴 건너뛰기




Volumn 27, Issue SUPPL. 2, 2007, Pages

Intravenous versus oral iron supplementation in peritoneal dialysis patients

Author keywords

Darbepoetin; Erythropoietin; Ferritin; Hemoglobin; Iron economics; Prospective studies

Indexed keywords

ERYTHROPOIETIN; FERRIC HYDROXIDE SUCROSE; FERROUS FUMARATE; FERROUS GLUCONATE; FERROUS SULFATE; FERUMOXYTOL; HEMOGLOBIN; HISTAMINE H2 RECEPTOR ANTAGONIST; IRON; IRON DEXTRAN; IRON POLYMALTOSE; IRON SACCHARATE; PHOSPHATE BINDING AGENT; PLACEBO; POLYPEPTIDE;

EID: 35748951336     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper
Times cited : (12)

References (51)
  • 1
    • 0029848803 scopus 로고    scopus 로고
    • Erythropoietin in chronic renal failure
    • Valderrabano F. Erythropoietin in chronic renal failure. Kidney Int 1996; 50:1373-91.
    • (1996) Kidney Int , vol.50 , pp. 1373-1391
    • Valderrabano, F.1
  • 2
    • 0032739951 scopus 로고    scopus 로고
    • A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (the SLEEPO study)
    • Benz RL, Pressman MR, Hovick ET, Peterson DD. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (the SLEEPO study). Am J Kidney Dis 1999; 34:1089-95.
    • (1999) Am J Kidney Dis , vol.34 , pp. 1089-1095
    • Benz, R.L.1    Pressman, M.R.2    Hovick, E.T.3    Peterson, D.D.4
  • 3
    • 0032949266 scopus 로고    scopus 로고
    • Strategies for iron supplementation: Oral versus intravenous
    • Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int 1999; 55(Suppl 69):S61-6.
    • (1999) Kidney Int , vol.55 , Issue.SUPPL. 69
    • Macdougall, I.C.1
  • 4
    • 0032852221 scopus 로고    scopus 로고
    • Optimizing erythropoietin therapy
    • Macdougall IC. Optimizing erythropoietin therapy. Curr Opin Hematol 1999; 6:121-6.
    • (1999) Curr Opin Hematol , vol.6 , pp. 121-126
    • Macdougall, I.C.1
  • 5
    • 19044397278 scopus 로고    scopus 로고
    • Results of the European Survey on Anaemia Management 2003 (ESAM 2003): Current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years
    • Jacobs C, Frei D, Perkins AC. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. Nephrol Dial Transplant 2005; 20(Suppl 3):iii3-24.
    • (2005) Nephrol Dial Transplant , vol.20 , Issue.SUPPL. 3
    • Jacobs, C.1    Frei, D.2    Perkins, A.C.3
  • 6
    • 0026032944 scopus 로고
    • Iron deficiency in maintenance hemodialysis patients: Assessment of diagnosis criteria and of three different iron treatments
    • Allegra V, Mengozzi G, Vasile A. Iron deficiency in maintenance hemodialysis patients: assessment of diagnosis criteria and of three different iron treatments. Nephron 1991; 57:175-82.
    • (1991) Nephron , vol.57 , pp. 175-182
    • Allegra, V.1    Mengozzi, G.2    Vasile, A.3
  • 7
    • 0029952883 scopus 로고    scopus 로고
    • A randomized controlled study of iron supplementation in patients treated with erythropoietin
    • Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50:1694-9.
    • (1996) Kidney Int , vol.50 , pp. 1694-1699
    • Macdougall, I.C.1    Tucker, B.2    Thompson, J.3    Tomson, C.R.4    Baker, L.R.5    Raine, A.E.6
  • 8
    • 0001772629 scopus 로고
    • Management of iron substitution during r-HuEPO therapy in chronic renal failure patients
    • Schaefer RM, Schaefer L. Management of iron substitution during r-HuEPO therapy in chronic renal failure patients. Erythropoiesis 1992; 3:71-5.
    • (1992) Erythropoiesis , vol.3 , pp. 71-75
    • Schaefer, R.M.1    Schaefer, L.2
  • 9
    • 1842334437 scopus 로고    scopus 로고
    • Management of iron deficiency in renal anemia: Guidelines for the optimal therapeutic approach in erythropoietin-treated patients
    • Drueke TB, Bárány P, Cazzola M, Eschbach JW, Grutzmacher P, Kaltwasser JP, et al. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients. Clin Nephrol 1997; 48:1-8.
    • (1997) Clin Nephrol , vol.48 , pp. 1-8
    • Drueke, T.B.1    Bárány, P.2    Cazzola, M.3    Eschbach, J.W.4    Grutzmacher, P.5    Kaltwasser, J.P.6
  • 10
    • 0029128840 scopus 로고
    • Evidence-based recommendations for the clinical use of recombinant human erythropoietin
    • Muirhead N, Bargman J, Burgess E, Jindal KK, Levin A, Nolin L, et al. Evidence-based recommendations for the clinical use of recombinant human erythropoietin. Am J Kidney Dis 1995; 26(Suppl 1):S1-24.
    • (1995) Am J Kidney Dis , vol.26 , Issue.SUPPL. 1
    • Muirhead, N.1    Bargman, J.2    Burgess, E.3    Jindal, K.K.4    Levin, A.5    Nolin, L.6
  • 11
    • 0031044128 scopus 로고    scopus 로고
    • Iron management in end-stage renal disease
    • Fishbane S, Maesaka JK. Iron management in end-stage renal disease. Am J Kidney Dis 1997; 29:319-33.
    • (1997) Am J Kidney Dis , vol.29 , pp. 319-333
    • Fishbane, S.1    Maesaka, J.K.2
  • 13
    • 4344581912 scopus 로고    scopus 로고
    • Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure
    • Locatelli F, Aljama P, Bárány P, Canaud B, Carrera F, Eckardt KU, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19(Suppl 2):ii1-47.
    • (2004) Nephrol Dial Transplant , vol.19 , Issue.SUPPL. 2
    • Locatelli, F.1    Aljama, P.2    Bárány, P.3    Canaud, B.4    Carrera, F.5    Eckardt, K.U.6
  • 14
    • 0035228407 scopus 로고    scopus 로고
    • IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis 2001; 37(Suppl 1):S182-238.
    • IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis 2001; 37(Suppl 1):S182-238.
  • 15
    • 35748936392 scopus 로고    scopus 로고
    • Pollock CA, Saltissi D, Roger S, Healy H, Barratt L, Elder G, et al. Biochemical and haematological targets. In: Knight J, Chu R, Smith J, Gerard J, eds. The CARI Guidelines. Sydney: Excerpta Medica Communications; 2000: 19-26.
    • Pollock CA, Saltissi D, Roger S, Healy H, Barratt L, Elder G, et al. Biochemical and haematological targets. In: Knight J, Chu R, Smith J, Gerard J, eds. The CARI Guidelines. Sydney: Excerpta Medica Communications; 2000: 19-26.
  • 16
    • 0033144635 scopus 로고    scopus 로고
    • Clinical practice guidelines for the management of anemia coexistent with chronic renal failure
    • Barrett BJ, Fenton SS, Ferguson B, Halligan P, Langlois S, Mccready WG, et al. Clinical practice guidelines for the management of anemia coexistent with chronic renal failure. J Am Soc Nephrol 1999; 10(Suppl 13):S292-6.
    • (1999) J Am Soc Nephrol , vol.10 , Issue.SUPPL. 13
    • Barrett, B.J.1    Fenton, S.S.2    Ferguson, B.3    Halligan, P.4    Langlois, S.5    Mccready, W.G.6
  • 17
    • 9644295720 scopus 로고    scopus 로고
    • Safety of intravenous iron in clinical practice: Implications for anemia management protocols
    • Aronoff GR. Safety of intravenous iron in clinical practice: implications for anemia management protocols. J Am Soc Nephrol 2004; 15(Suppl 2):S99-106.
    • (2004) J Am Soc Nephrol , vol.15 , Issue.SUPPL. 2
    • Aronoff, G.R.1
  • 20
    • 25644432169 scopus 로고    scopus 로고
    • Trends in intravenous iron use among dialysis patients in the United States (1994-2002)
    • St Peter WL, Obrador GT, Roberts TL, Collins AJ. Trends in intravenous iron use among dialysis patients in the United States (1994-2002). Am J Kidney Dis 2005; 46:650-60.
    • (2005) Am J Kidney Dis , vol.46 , pp. 650-660
    • St Peter, W.L.1    Obrador, G.T.2    Roberts, T.L.3    Collins, A.J.4
  • 21
    • 0028966230 scopus 로고
    • Subcutaneous epoetin beta in renal anemia: An open multicenter dose titration study of patients on continuous peritoneal dialysis
    • Bárány P, Clyne N, Hylander B, Johansson AC, Simonsen O, Larsson R, et al. Subcutaneous epoetin beta in renal anemia: an open multicenter dose titration study of patients on continuous peritoneal dialysis. Perit Dial Int 1995; 15:54-60.
    • (1995) Perit Dial Int , vol.15 , pp. 54-60
    • Bárány, P.1    Clyne, N.2    Hylander, B.3    Johansson, A.C.4    Simonsen, O.5    Larsson, R.6
  • 23
    • 0027970022 scopus 로고
    • Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients
    • Nyvad O, Danielsen H, Madsen S. Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients. Lancet 1994; 344:1305-6.
    • (1994) Lancet , vol.344 , pp. 1305-1306
    • Nyvad, O.1    Danielsen, H.2    Madsen, S.3
  • 25
    • 0027033409 scopus 로고
    • Failure of CAPD patients to respond to an oral iron absorption test
    • Domoto DT, Martin KJ. Failure of CAPD patients to respond to an oral iron absorption test. Adv Perit Dial 1992; 8:102-4.
    • (1992) Adv Perit Dial , vol.8 , pp. 102-104
    • Domoto, D.T.1    Martin, K.J.2
  • 26
    • 0035113469 scopus 로고    scopus 로고
    • Iron absorption after single pharmacological oral iron loading test in patients on chronic peritoneal dialysis and in healthy volunteers
    • Bastani B, Islam S, Boroujerdi N. Iron absorption after single pharmacological oral iron loading test in patients on chronic peritoneal dialysis and in healthy volunteers. Perit Dial Int 2000; 20:662-6.
    • (2000) Perit Dial Int , vol.20 , pp. 662-666
    • Bastani, B.1    Islam, S.2    Boroujerdi, N.3
  • 27
    • 0035173145 scopus 로고    scopus 로고
    • Intravenous iron for CAPD populations: Proactive or reactive strategies?
    • Richardson D, Bartlett C, Jolly H, Will EJ. Intravenous iron for CAPD populations: proactive or reactive strategies? Nephrol Dial Transplant 2001; 16:115-19.
    • (2001) Nephrol Dial Transplant , vol.16 , pp. 115-119
    • Richardson, D.1    Bartlett, C.2    Jolly, H.3    Will, E.J.4
  • 28
    • 0032940723 scopus 로고    scopus 로고
    • Iron status and iron supplementation in peritoneal dialysis patients
    • Vychytil A, Haag-Weber M. Iron status and iron supplementation in peritoneal dialysis patients. Kidney Int 1999; 55(Suppl 69):S71-8.
    • (1999) Kidney Int , vol.55 , Issue.SUPPL. 69
    • Vychytil, A.1    Haag-Weber, M.2
  • 29
    • 0031897948 scopus 로고    scopus 로고
    • Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: A single center comparative study
    • Ahsan N. Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: a single center comparative study. J Am Soc Nephrol 1998; 9:664-8.
    • (1998) J Am Soc Nephrol , vol.9 , pp. 664-668
    • Ahsan, N.1
  • 30
    • 0033647567 scopus 로고    scopus 로고
    • Infusion of total dose iron versus oral iron supptementation in ambulatory peritoneal dialysis patients: A prospective, crossover trial
    • Ahsan N. Infusion of total dose iron versus oral iron supptementation in ambulatory peritoneal dialysis patients: a prospective, crossover trial. Adv Perit Dial 2000; 16:80-4.
    • (2000) Adv Perit Dial , vol.16 , pp. 80-84
    • Ahsan, N.1
  • 31
    • 0030065969 scopus 로고    scopus 로고
    • Intravenous ferric saccharate as an iron supplement in dialysis patients
    • Silverberg DS, Blum M, Peer G, Kaplan E, Iaina A. Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 1996; 72:413-17.
    • (1996) Nephron , vol.72 , pp. 413-417
    • Silverberg, D.S.1    Blum, M.2    Peer, G.3    Kaplan, E.4    Iaina, A.5
  • 32
    • 0034838979 scopus 로고    scopus 로고
    • A prospective cross-over trial comparing intermittent intravenous and continuous oral iron supplementation in peritoneal dialysis patients
    • Johnson DW, Herzig KA, Gissane R, Campbell SB, Hawley CM, Isbel NM. A prospective cross-over trial comparing intermittent intravenous and continuous oral iron supplementation in peritoneal dialysis patients. Nephrol Dial Transplant 2001; 16:1879-84.
    • (2001) Nephrol Dial Transplant , vol.16 , pp. 1879-1884
    • Johnson, D.W.1    Herzig, K.A.2    Gissane, R.3    Campbell, S.B.4    Hawley, C.M.5    Isbel, N.M.6
  • 33
    • 4243888891 scopus 로고    scopus 로고
    • Reduced nPCR in patients with gastrointestinal side effects due to ferrous sulfate [Abstract]
    • Fishbane S, Goreja MAJ, Maesaka JK. Reduced nPCR in patients with gastrointestinal side effects due to ferrous sulfate [Abstract]. J Am Soc Nephrol 1998; 9:248A.
    • (1998) J Am Soc Nephrol , vol.9
    • Fishbane, S.1    Goreja, M.A.J.2    Maesaka, J.K.3
  • 34
  • 35
    • 0000132208 scopus 로고    scopus 로고
    • Intravenous iron hydroxy saccharate: Establishing the optimum dose [Abstract]
    • Chandler GH. Intravenous iron hydroxy saccharate: establishing the optimum dose [Abstract]. J Am Soc Nephrol 2001; 8:217.
    • (2001) J Am Soc Nephrol , vol.8 , pp. 217
    • Chandler, G.H.1
  • 37
    • 0033012811 scopus 로고    scopus 로고
    • Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans
    • Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis 1999; 33:464-70.
    • (1999) Am J Kidney Dis , vol.33 , pp. 464-470
    • Faich, G.1    Strobos, J.2
  • 38
    • 0019434645 scopus 로고
    • Iron and the sex difference in heart disease risk
    • Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1981; 1:1293-4.
    • (1981) Lancet , vol.1 , pp. 1293-1294
    • Sullivan, J.L.1
  • 39
    • 0031949458 scopus 로고    scopus 로고
    • Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency
    • Patruta SI, Edlinger R, Sunder-Plassmann G, Horl WH. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 1998; 9:655-63.
    • (1998) J Am Soc Nephrol , vol.9 , pp. 655-663
    • Patruta, S.I.1    Edlinger, R.2    Sunder-Plassmann, G.3    Horl, W.H.4
  • 40
    • 0028960847 scopus 로고
    • Risk factors for bacterial infections in chronic haemodialysis adult patients: A multicentre prospective survey
    • Hoen B, Kessler M, Hestin D, Mayeux D. Risk factors for bacterial infections in chronic haemodialysis adult patients: a multicentre prospective survey. Nephrol Dial Transplant 1995; 10:377-81.
    • (1995) Nephrol Dial Transplant , vol.10 , pp. 377-381
    • Hoen, B.1    Kessler, M.2    Hestin, D.3    Mayeux, D.4
  • 41
    • 0031959987 scopus 로고    scopus 로고
    • EPIBACDIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients
    • Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998; 9:869-76.
    • (1998) J Am Soc Nephrol , vol.9 , pp. 869-876
    • Hoen, B.1    Paul-Dauphin, A.2    Hestin, D.3    Kessler, M.4
  • 42
    • 0034896249 scopus 로고    scopus 로고
    • Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharate in peritoneal dialysis patients
    • Prakash S, Walele A, Dimkovic N, Bargman J, Vas S, Oreopoulos D. Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharate in peritoneal dialysis patients. Perit Dial Int 2001; 21:290-5.
    • (2001) Perit Dial Int , vol.21 , pp. 290-295
    • Prakash, S.1    Walele, A.2    Dimkovic, N.3    Bargman, J.4    Vas, S.5    Oreopoulos, D.6
  • 43
    • 0037159304 scopus 로고    scopus 로고
    • Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease
    • Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002; 106:2212-17.
    • (2002) Circulation , vol.106 , pp. 2212-2217
    • Drueke, T.1    Witko-Sarsat, V.2    Massy, Z.3    Descamps-Latscha, B.4    Guerin, A.P.5    Marchais, S.J.6
  • 47
    • 0013992155 scopus 로고
    • Side-effects of oral iron therapy. A double-blind study of different iron compounds in tablet form
    • Hallberg L, Ryttinger L, Solvell L. Side-effects of oral iron therapy. A double-blind study of different iron compounds in tablet form. Acta Med Scand Suppl 1966; 459:3-10.
    • (1966) Acta Med Scand Suppl , vol.459 , pp. 3-10
    • Hallberg, L.1    Ryttinger, L.2    Solvell, L.3
  • 48
    • 0033800008 scopus 로고    scopus 로고
    • Clinical studies of HIP: An oral heme-iron product
    • Seligman PA, Moore GM, Schleicher RB. Clinical studies of HIP: an oral heme-iron product. Nutr Res 2000; 20: 1279-86.
    • (2000) Nutr Res , vol.20 , pp. 1279-1286
    • Seligman, P.A.1    Moore, G.M.2    Schleicher, R.B.3
  • 49
    • 0030743156 scopus 로고    scopus 로고
    • Iron absorption from the whole diet in men: How effective is the regulation of iron absorption?
    • Hallberg L, Hulten L, Gramatkovski E. Iron absorption from the whole diet in men: how effective is the regulation of iron absorption? Am J Clin Nutr 1997; 66:347-56.
    • (1997) Am J Clin Nutr , vol.66 , pp. 347-356
    • Hallberg, L.1    Hulten, L.2    Gramatkovski, E.3
  • 50


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.